ECSP21062210A - Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias - Google Patents

Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias

Info

Publication number
ECSP21062210A
ECSP21062210A ECSENADI202162210A ECDI202162210A ECSP21062210A EC SP21062210 A ECSP21062210 A EC SP21062210A EC SENADI202162210 A ECSENADI202162210 A EC SENADI202162210A EC DI202162210 A ECDI202162210 A EC DI202162210A EC SP21062210 A ECSP21062210 A EC SP21062210A
Authority
EC
Ecuador
Prior art keywords
treatment
amino acid
acid derivatives
inflammatory diseases
compounds
Prior art date
Application number
ECSENADI202162210A
Other languages
English (en)
Inventor
Daniel Paris
Chao Jin
Michael Mullan
Original Assignee
The Roskamp Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Roskamp Inst filed Critical The Roskamp Inst
Publication of ECSP21062210A publication Critical patent/ECSP21062210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente divulgación proporciona ciertos derivados de aminoácidos que inhiben la activación de NF-kB y, por lo tanto, son útiles para el tratamiento de enfermedades inflamatorias. También se proporcionan composiciones farmacéuticas que contienen tales compuestos y procesos para preparar tales compuestos.
ECSENADI202162210A 2019-01-22 2021-08-20 Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias ECSP21062210A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795549P 2019-01-22 2019-01-22
US201962871951P 2019-07-09 2019-07-09
PCT/US2020/014636 WO2020154420A2 (en) 2019-01-22 2020-01-22 Amino acid derivatives for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
ECSP21062210A true ECSP21062210A (es) 2022-06-30

Family

ID=69726748

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202162210A ECSP21062210A (es) 2019-01-22 2021-08-20 Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias

Country Status (17)

Country Link
US (1) US20220081415A1 (es)
EP (1) EP3924349A2 (es)
JP (1) JP2022524571A (es)
KR (1) KR20210141930A (es)
CN (1) CN113614074A (es)
AU (1) AU2020211980A1 (es)
BR (1) BR112021014372A2 (es)
CA (1) CA3127246A1 (es)
CL (1) CL2021001944A1 (es)
CO (1) CO2021010931A2 (es)
EC (1) ECSP21062210A (es)
IL (1) IL284980A (es)
MA (1) MA54940A (es)
MX (1) MX2021008748A (es)
SG (1) SG11202107977TA (es)
WO (1) WO2020154420A2 (es)
ZA (1) ZA202105229B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6218390B1 (en) * 1998-12-17 2001-04-17 Synaptic Pharmaceutical Corporation Morpholinone and morpholine derivatives and uses thereof
CN102439000A (zh) * 2009-05-01 2012-05-02 普罗菲克图斯生物科学股份有限公司 抑制核因子-κ(B)-(NF-κB)的苯甲酰胺和萘甲酰胺衍生物

Also Published As

Publication number Publication date
US20220081415A1 (en) 2022-03-17
EP3924349A2 (en) 2021-12-22
MA54940A (fr) 2021-12-22
ZA202105229B (en) 2022-12-21
SG11202107977TA (en) 2021-08-30
WO2020154420A2 (en) 2020-07-30
BR112021014372A2 (pt) 2021-09-28
CN113614074A (zh) 2021-11-05
WO2020154420A4 (en) 2020-11-12
CO2021010931A2 (es) 2022-01-17
CL2021001944A1 (es) 2022-05-06
IL284980A (en) 2021-09-30
KR20210141930A (ko) 2021-11-23
WO2020154420A3 (en) 2020-09-10
JP2022524571A (ja) 2022-05-09
AU2020211980A1 (en) 2021-08-19
MX2021008748A (es) 2022-01-24
CA3127246A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
UY37656A (es) Compuestos que inhiben la proteína mcl-1
CL2019002255A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas.
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2019001092A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas.
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
DOP2018000238A (es) Inhibidores del potenciador del homólogo zeste 2
CL2021003568A1 (es) Compuestos heteroaromáticos como inhibidores de vanina (divisional de solicitud n° 202101198)
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
ECSP21013743A (es) Compuestos heteroaromáticos como inhibidores de vanina
CL2022003703A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos
AR117844A1 (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina
ECSP21062210A (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
WO2016187620A3 (en) Anti-cancer compounds
CL2021000618A1 (es) Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo
CO2019001967A2 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1